Literature DB >> 11499842

Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas.

Z Suo1, H S Berner, B Risberg, M G Karlsson, J M Nesland.   

Abstract

The presence of estrogen receptors (ERs) in breast carcinomas is important for clinical response to endocrine therapy. However, the cellular mechanisms following ER activation are not fully understood. It has been indicated that expression of the ER is associated with the expression of c-erbB-4. To address this question, 103 breast carcinoma samples were studied using reverse transcriptase polymerase chain reaction (RT-PCR) analysis after application of a microselection method for RNA isolation. Total RNA for RT-PCR was isolated from 20-microm-thick frozen sections, which were made from microselected areas. Paraffin blocks from 98 of these 103 tumors were also immunohistochemically examined. Significant associations between ER-alpha and c-erbB-4 mRNA and protein expressions were found in the present study with both methods. One-fourth of the tumors did not express ER-alpha (22%, 24%, and 26% with chemical binding, immunohistochemistry, and RT-PCR, respectively). About one-half of the ER-alpha negative tumors did not express c-erbB-4 on both mRNA and protein levels (48% with RT-PCR and 46% with immunohistochemistry, P=0.001 for both methods). The endocrine therapy responsive breast cancer cell lines MCF-7 and T47-D were positive for both ER-alpha and c-erbB-4 expression, while the endocrine therapy nonresponsive breast cancer cell lines MDA-MD-231 and SK-BR-3 were not. Thus, we confirm the association between the expression of ER-alpha and c-erbB-4 mRNA and protein in breast carcinomas, indicating a role for c-erbB-4 in estrogen signal transduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499842     DOI: 10.1007/s004280000392

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

Review 1.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

2.  HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.

Authors:  Wen Han; Frank E Jones
Journal:  Biochem Biophys Res Commun       Date:  2013-12-11       Impact factor: 3.575

3.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.

Authors:  A J Lodge; J J Anderson; W J Gullick; B Haugk; R C F Leonard; B Angus
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

Review 4.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

Review 5.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

Review 6.  The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

Authors:  H Shelton Earp; Benjamin F Calvo; Carolyn I Sartor
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

7.  Expression of Ephb2 and Ephb4 in breast carcinoma.

Authors:  Qinghua Wu; Zhenhe Suo; Bjørn Risberg; Mats G Karlsson; Kenneth Villman; Jahn M Nesland
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

8.  Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.

Authors:  Eunkyung Ko; Seong-Eun Park; Eun Yoon Cho; Yujin Kim; Jung-Ah Hwang; Yeon-Su Lee; Seok Jin Nam; Saik Bang; Joobae Park; Duk-Hwan Kim
Journal:  Breast Cancer Res       Date:  2010-11-23       Impact factor: 6.466

9.  Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Authors:  S E Clark; J Warwick; R Carpenter; R L Bowen; S W Duffy; J L Jones
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

10.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.